Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Depreciation & Amortization (CF) (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $885000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 31.5% to $885000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.4 million, a 22.35% decrease, with the full-year FY2025 number at $5.4 million, down 20.04% from a year prior.
  • Depreciation & Amortization (CF) was $885000.0 for Q4 2025 at Aytu Biopharma, up from $803000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.3 million in Q2 2021 to a low of $803000.0 in Q3 2025.
  • A 5-year average of $1.9 million and a median of $2.1 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 71.85% in 2021, then crashed 40.18% in 2024.
  • Aytu Biopharma's Depreciation & Amortization (CF) stood at $2.7 million in 2021, then dropped by 17.53% to $2.2 million in 2022, then fell by 18.81% to $1.8 million in 2023, then fell by 27.86% to $1.3 million in 2024, then tumbled by 31.5% to $885000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Depreciation & Amortization (CF) are $885000.0 (Q4 2025), $803000.0 (Q3 2025), and $1.3 million (Q2 2025).